WHSTS ANY DEAL WORTH TO HOLDERS HERE EXPECTATION SP21 Mar 2025 07:56
Relevant therapy markets in this area are forecast to reach global sales of
c.$360 billion by 2030. There have been 11 relevant therapy product licensing
deals averaging $1bn total deal value in last 2 years. (UBS Investment Banking
Reports).
Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:
"These stunning results clearly demonstrate the unique MOA of P140 and this
data adds significantly to our ongoing discussions with potential partners and
our objective to secure the optimum deal(s) for our shareholders."
Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma
Biotech, said:
"These results are extremely compelling. Not only do they validate our MOA,
they also indicate that P140 has the possibility to become a central treatment
for a number of autoimmune diseases. Patients can be very hopeful, I certainly
am!"
10p 20p 30 40p